ANDREW L. PECORA, MD, OF JOHN THEURER CANCER CENTER, RECEIVES 2nd Annual PM360 UBER ELITE AWARD

June 2, 2016 03:46 PM

PM360, the premier information resource for marketing decision makers in the pharmaceutical and medical device sectors, today announced that Andrew L. Pecora, MD, Chief Innovation Officer and Vice President, Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ is the recipient of the PM360 Uber ELITE Award. Established last year, the PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today.

Dr. Pecora will receive the award at the PM360 ELITE celebration and networking cocktail party at the Top of The Standard Hotel in Manhattan’s Meatpacking District on Tuesday, July 12, 2016 at 7:00 pm. Dr. Pecora is also featured in the May issue of PM360.

“We established the ELITE Awards to recognize individuals whose work is making a significant impact on the life sciences industry,” says Anna Stashower, CEO/Publisher, PM360. “We recognize multiple professionals in several categories, but the Uber ELITE award honors an individual of incredible achievement, one person who embodies exceptionalism and is accomplishing innovative and inspirational deeds. Dr. Pecora is a champion for breakthrough patient care, research, and pharmaceutical industry collaboration, who advances the goal of making a meaningful difference in the lives of people living with cancer.”

Dr. Pecora has been on the leading edge of many cancer care advances, and is recognized as one of the world’s foremost experts in blood and marrow stem cell transplantation, cellular medicine and immunology research. In 1989, he spearheaded the development of John Theurer Cancer Center’s Adult Blood and Marrow Stem Cell Transplantation Program and is responsible for many advancements used in stem cell transplantation today. In 1990, Dr. Pecora performed the first of what are now nearly 6,000 bone marrow transplants at the Center. Dr. Pecora’s current research involves developing vaccines and other cellular medicine techniques that boost the capabilities of a patient’s own immune system to fight cancer and targeted therapies that destroy cancer cells. He has also been a driving force in the establishment of Cancer Outcomes Tracking Analysis (COTA), a technology platform that improves clinical outcomes and reduces wasteful spend in oncology through precise classification of illness and a smarter use of data.

 

Dr. Pecora is also a strong advocate for collaboration between clinical experts and pharmaceutical industry scientists, viewing partnership as essential in accelerating treatment advances. Today, drugs from important partners in cancer clinical research, Bristol-Myers Squibb, Celgene and Merck, have come to market faster, owing in part to the John Theurer Cancer Center’s participation in clinical trials and shared peer-review data.

 

“I’m honored to accept this award from PM360,” says Dr. Pecora. “We are at a critical point in the treatment and management of cancer. New genome-based therapeutic solutions, the ability to power a patient’s own immune system to fight cancer and the advent of the unprecedented potential to leverage a patient’s unique genetic profile to improve clinical outcomes opens up a new world of hope and possibilities in the treatment of people with cancer. Collaboration among all of us who, in some way, touch the patient—clinicians, researchers, hospital systems, industry, policy makers and patient advocates—is critical to advancing to advancing this new vision in the service of patients and their families.”

 

Dr. Pecora will also serve as the keynote speaker at the PM360 ELITE event on July 12. Tickets are available for purchase at www.pm360online.com/elitetickets.

About PM360

PM360is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.

The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.

By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.

 

Back

 
 


best-hospitals-cardiology    high-performing-indicator-heartfailure    high-performing-indicator-heartbypass     HG_Americas_50_Best_Award_Image_2014      HG_Americas_100_Best_Stroke_Care_Award_Image_2014        HG_Americas_100_Best_Pulmonary_Care_Award_Image_2014     red-bulllgbt      tkc_homepagelogo-2
 


Translation service provided by Google. HackensackUMC is not responsible for the accuracy of translation or any other
aspect of service provided by the GoogleTranslate tool. Users should not make medical decisions without first consulting
with their physician.
 
Site Map|Privacy Policy|Media Center
©2016 Hackensack University Medical Center. All rights reserved.
close (X)